Effect of abrocitinib and dupilumab on eosinophil levels in patients with moderate‐to‐severe atopic dermatitis
Abstract Background Eosinophilia is common in patients with atopic dermatitis (AD). Abrocitinib, an oral Janus kinase‐1 inhibitor and dupilumab, an anti-interleukin‐4 receptor‐α antibody, are approved for moderate‐to‐severe AD. Dupilumab has been associated with transient eosinophilia. Objectives To...
Сохранить в:
Главные авторы: | , , , , , , , , , , , , |
---|---|
Формат: | |
Опубликовано: |
Wiley,
2023-09-01T00:00:00Z.
|
Предметы: | |
Online-ссылка: | Connect to this object online. |
Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|
Internet
Connect to this object online.3rd Floor Main Library
Шифр: |
A1234.567 |
---|---|
Копировать 1 | Доступно |